IFAM
VKTX icon

Institutional & Family Asset Management’s Viking Therapeutics VKTX Stock Holding History

Institutional & Family Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-14
Closed -$1.15K – 783
2024
Q1 		$1.15K Buy
+14
New +$623 ﹤0.01% 615
2023
Q3 		– Sell
-100
Closed -$1.62K – 766
2023
Q2 		$1.62K Buy
+100
New +$2.1K ﹤0.01% 583

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Institutional & Family Asset Management's VKTX Position: Q2 2024 in Review

Institutional & Family Asset Management sold out of Viking Therapeutics (VKTX) in Q2 2024, closing a stake of 14 shares — an estimated $1.15K sold.

Institutional & Family Asset Management first reported a position in VKTX in Q2 2023 and held it in 2 quarters. The position peaked at $1.62K in Q2 2023. 387 funds tracked by Wall St. Rank hold VKTX as of Q2 2024.

  • Institutional & Family Asset Management reported no remaining Viking Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Institutional & Family Asset Management sold 14 Viking Therapeutics shares in Q2 2024, an estimated $1.15K.
  • Institutional & Family Asset Management first reported a position in Viking Therapeutics in Q2 2023 and held it in 2 quarters.
  • Institutional & Family Asset Management's Viking Therapeutics position peaked at $1.62K in Q2 2023.
  • 387 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2024.

Based on Institutional & Family Asset Management's 13F filing for Q2 2024, filed 5 Jul 2024.